Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months

Journal of Rheumatology

Volumn 25, Issue 2, 1998, Pages 285-289

  Van Vollenhoven, Ronald F ^a,b,c   Morabito, Lance M ^a,c   Engleman, Edgar G ^a,d,e   McGuire, James L ^a,d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Medicine

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^d Department of Pathology ^*

^e Stanford California and Cofounder   (United States)

Author keywords

Dehydroepiandrosterone; Systemic lupus erythematosus; Treatment

Indexed keywords

PRASTERONE; PRASTERONE SULFATE; PREDNISONE; TESTOSTERONE;

ACNE; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HIRSUTISM; HUMAN; LONGITUDINAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

ADULT; DEHYDROEPIANDROSTERONE; DEHYDROEPIANDROSTERONE SULFATE; FEASIBILITY STUDIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; POSTMENOPAUSE; PREDNISONE; PREMENOPAUSE; PROSPECTIVE STUDIES; TESTOSTERONE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0031910776     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Michel CJ, McKenna CH, Elveback LR, Kaslow RA, Kurland LT. Epidemiology of systemic lupus erythematosus and other connective tissue diseases in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 1985;60:105-13.
2. Mund A, Simson J, Rothfield N. Effect of pregnancy on the course of systemic lupus erythematosus. JAMA 1963;183:917-20.
3. Petri M, Howard D, Repke J. Frequency of lupus flare in pregnancy. The Hopkins Lupus Pregnancy Center experience. Arthritis Rheum 1991;34:1538-45.
4. Lockshin MD. Does lupus flare during pregnancy? Lupus 1993;2:1-2.
5. Jungers P, Dougados M, Pelissier M, et al. Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis Rheum 1982;25:618-23.
6. Lahita RG, Bradlow HL, Kunkel HG, Fishman J. Alterations of estrogen metabolism in systemic lupus erythematosus. Arthritis Rheum 1979;22:1195-8.
7. Siiteri PK, Jones LA, Roubinian J, Talal N. Sex steroids and the immune system. I. Sex difference in autoimmune disease in NZB/NZW hybrid mice. J Steroid Biochem 1980;12:425-32.
8. 1 females of different ages. Arthritis Rheum 1980;23:41-8.
9. Lahita RG, Cheng CY, Monder C, Bardin CW. Experience with 19-nortestosterone in the therapy of systemic lupus erythematosus: worsened disease after treatment with 19-nortestosterone in men and lack of improvement in women. J Rheumatol 1992;19:447-55.
10. Parker LN. Control of adrenal androgen secretion. Endocrin Metab Clin N Am 1991;20:401-21.
11. Mortola JF, Yen SC. The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. J Clin Endocrinol Metab 1990;71:696-704.
12. Nestler JE, Barlascini CO, Clare JN, Blackard WG. Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J Clin Endocrinol Metab 1988;66:57-69.
13. Felt V, Starka L. Metabolic effects of DHEA and atromid in patients with hyperlipaemia. Cor Vasa 1966;8:40-4.
14. Abrahamsson L, Hackl H. Catabolic effects and the influence on hormonal variables under the treatment with gynodian-depot or DHEA oenanthate. Maturitas 1981;3:225-34.
15. Ebeling P, Koivisto VA. Physiological importance of dehydroepiandrosterone. Lancet 1994;343:1479-81.
16. Daynes RA, Dudley DJ, Araneo BA. Regulation of murine lymphokine production in vivo. II. Dehydroepiandrosterone is a natural enhancer of interleukin 2 synthesis by helper T cells. Eur J Immunol 1990;20:793-802.
17. Daynes RA, Araneo BA. Natural regulators of T-cell lymphokine production in vivo. J Immunother 1992;12:174-9.
18. Suzuki T, Suzuki N, Daynes RA, Engleman EG. Dehydropiandrosterone enhances IL-2 production and cytotoxic effector function of human T cells. Clin Immunol Immunopathol 1991;61:202-11.
19. Suzuki T, Suzuki N, Engleman EG, Mizushima Y, Sakane T. Low serum levels of dehydroepiandrosterone therapy may cause deficient IL-2 production by lymphocytes in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1995;99:251-5.
20. Jungers P, Nahoul K, Pelissier C, Dougados M, Tron F, Bach J-F. Low plasma androgens in women with active or quiescent systemic lupus erythematosus. Arthritis Rheum 1982;25:454-62.
21. Lahita RG, Bradlow HL, Ginzler E, Pang S, New M. Low plasma androgens in women with systemic lupus erythematosus. Arthritis Rheum 1987;30:241-8.
22. Lucas JA, Ahmed AA, Casey ML, MacDonald PC. Prevention of autoantibody formation and prolonged survival in New Zealand Black/New Zealand White F, mice fed dehydroisoandrosterone. J Clin Invest 1985;75:2091-3.
23. van Vollenhoven RF, McDevitt HO. Studies of the treatment of nephritis in NZB/NZW mice with dehydroepiandrosterone [abstract]. Arthritis Rheum 1992;35 Suppl:S207.
24. van Vollenhoven RF, Engleman EG, McGuire JL. An open study of dehydroepiandrosterone in systemic lupus erythematosus. Arthritis Rheum 1994;37:1305-10.
25. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI: a Disease Activity Index for lupus patients. Arthritis Rheum 1992;35:630-40.
26. van Vollenhoven RF, Engleman EG, McGuire JL. Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheum 1995;38:1826-31.